Morgan Stanley analyst Patrick Wood lowered the firm’s price target on Bausch + Lomb (BLCO) to $18 from $19 and keeps an Equal Weight rating on ...

BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...

After completing $300 billion in healthcare deals over several decades, there is one deal Bausch and Lomb (BLCO) chairman and CEO Brent Saunders won't be making in 2025. The one for his contact ...

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.24 per share a year ago.

VAUGHAN, Ontario (AP) — VAUGHAN, Ontario (AP) — Bausch + Lomb Corporation (BLCO) on Wednesday reported a loss of $3 million in its fourth quarter. On a per-share basis, the Vaughan ...

Eyecare company Bausch + Lomb (NYSE:BLCO) reported in Q4 CY2024, with sales up 9.1% year on year to $1.28 billion. On the other hand, the company’s full-year revenue guidance of $4.98 billion at the ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2024 ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ...